Freshly published data from LivaNova’s pivotal ANTHEM-HFrEF trial hinted that vagal nerve stimulation might help patients with HFrEF, but the company’s early termination decision left some questions unanswered. To test the device, researchers randomized 532 HFrEF patients to receive VNS + GDMT or GDMT alone, tracking their CV health for a median of 16.9 months, […] The post Uncertainty Lingers on VNS for HF After Shortened Study appeared first on Cardiac Wire .